Oncology & Cancer

Zoledronic acid every 12 weeks noninferior in bone metastases

(HealthDay)—Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple ...

Oncology & Cancer

Early chemotherapy improves survival for men with prostate cancer

Two papers from UCL show that having early chemotherapy improves survival for men with prostate cancer. The papers, published in the Lancet and Lancet Oncology, report the results from the STAMPEDE clinical trial and a meta-analysis.

page 1 from 3